Researchers from the University of Tsukuba identified the protein MafB as a key molecular actor in the development of FSGS. They showed that MafB-lacking mice develop FSGS and that treatment of FSGS mice with atRA, an agent known to induce the production of MafB, partially reversed the development of the disease. These findings provide new insights into a potential novel therapeutic target for FSGS.
- One way to prevent cancer: map the fundamentals of how cells go awry
- How initiatives empowering employees can backfire
- Hot-button words trigger conservatives and liberals differently
- A CNIO team describes how a virus can cause diabetes
- From pills to powder: 1 in 3 high school seniors who misused prescription opioids later used heroin